Titre du document / Document title

Role of Raloxifene in breast cancer prevention in postmenopausal women: Clinical evidence and potential mechanisms of action

Auteur(s) / Author(s)

SPORN Michael B. ⁽¹⁾ ; DOWSETT Sherie A. ⁽²⁾ ; MERSHON John ⁽²⁾ ; BRYANT Henry U. ⁽²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Dartmouth Medical School, Hanover, New Hampshire, ETATS-UNIS
⁽²⁾ Eli Lilly and Company, Indianapolis, Indiana, ETATS-UNIS

Résumé / Abstract

Background: Raloxifene is a selective estrogen-receptor modulator (SERM) indicated for the prevention and treatment of osteoporosis in postmenopausal women. In the Multiple Outcomes of Raloxifene Evaluation (MORE) study, an osteoporosis treatment trial, raloxifene therapy was associated with a reduced incidence of invasive, estrogen receptor (ER)-positive breast cancer compared with placebo (relative risk, 0.16; 95% CI, 0.09-0.30). Objective: This review summarizes available preclinical and clinical data pertaining to a potential role for raloxifene in the prevention of breast cancer, and examines the mechanism of action by which raloxifene may exert an effect. Methods: Relevant articles were identified through a search of MEDLINE for English-language studies published between 1966 and January 2003. Search terms included raloxifene, keoxifene, tamoxifen, SERM, estrogen, estrogen receptor, breast, mammary, growth factors, and apoptosis. The reference lists of identified articles were reviewed for additional publications. Results: Both preclinical and clinical data suggest a role for raloxifene in the prevention of breast cancer. Like tamoxifen, raloxifene acts as an estrogen antagonist in breast tissue through competitive binding to the ER. Raloxifene may also inhibit breast tissue proliferation through mechanisms independent of the ER. Conclusions: Given raloxifene's mechanism of action and the preclinical evidence for its role in breast cancer prevention, a clinically favorable effect seems feasible. Results of ongoing clinical studies will provide evidence to support or refute the clinical findings of MORE and thus raloxifene's role in breast cancer prevention.

Revue / Journal Title

Clinical therapeutics   ISSN 0149-2918 

Source / Source

2004, vol. 26, n^o6, pp. 830-840 [11 page(s) (article)] (63 ref.)

Langue / Language

Anglais

Editeur / Publisher

Excerpta Medica, Belle Mead, NJ, ETATS-UNIS  (1977) (Revue)

Mots-clés anglais / English Keywords

Mammary gland diseases ; Non steroid compound ; Antiestrogen ; Antihormone ; Breast cancer ; Antineoplastic agent ; Hormonal receptor ; Estrogen receptor ; Mechanism of action ; Human ; Menopause ; Postmenopause ; Prevention ; Raloxifene ; Malignant tumor ;

Mots-clés français / French Keywords

Glande mammaire pathologie ; Composé non stéroïde ; Antioestrogène ; Antihormone ; Cancer du sein ; Anticancéreux ; Récepteur hormonal ; Récepteur oestrogène ; Mécanisme action ; Homme ; Ménopause ; Postménopause ; Prévention ; Raloxifène ; Tumeur maligne ;

Mots-clés espagnols / Spanish Keywords

Glándula mamaria patología ; Compuesto no esteroide ; Antiestrógeno ; Antihormona ; Cáncer del pecho ; Anticanceroso ; Receptor hormonal ; Receptor estrógeno ; Mecanismo acción ; Hombre ; Menopausia ; Postmenopausia ; Prevención ; Raloxifeno ; Tumor maligno ;

Mots-clés d'auteur / Author Keywords

raloxifene ; estrogen receptor ; breast cancer ; mechanism of action ;

Localisation / Location

INIST-CNRS, Cote INIST : 18353, 35400011377141.0030